Skip to content
penbutolol

Structure via PubChem · Public domain (PubChem)

EntityQ944244· pop 16· linked from 1,722 articles

penbutolol

Sign in to save

Also known as HOE-39-893d, HOE-893d, Levatol®, HOE 893D, HOE 893, Penbutololum, 2-Propanol, 1-(2-cyclopentylphenoxy)-3-((1,1-dimethylethyl)amino)-, (S)-

Penbutolol (brand names Levatol, Levatolol, Lobeta, Paginol, Hostabloc, Betapressin) is a medication in the class of beta blockers, used in the treatment of high blood pressure. Penbutolol is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective β blocker. Penbutolol is a sympathomimetic drug with properties allowing it to act as a partial agonist at β adrenergic receptors.

Chemical data

Formula
C18H29NO2
Molecular weight
291.4 g/mol
IUPAC name
(2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol
SMILES
CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O
InChIKey
KQXKVJAGOJTNJS-HNNXBMFYSA-N
XLogP
4.2
Polar surface area
41.5 Ų
H-bond donors
2
H-bond acceptors
3
Formal charge
0

via PubChem

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Small molecule
First approval
1987
Admin. routes
oral
Indications
cardiovascular disease

via ChEMBL · EBI

Wikidata facts

Mass
291.219829
Has use
medication
Show 9 more facts
Commons category
Penbutolol
chemical formula
C₁₈H₂₉NO₂
medical condition treated
arterial hypertension
World Health Organisation international non-proprietary name
penbutolol
canonical SMILES
CC(C)(C)NCC(COC1=CC=CC=C1C2CCCC2)O
isomeric SMILES
CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O
defined daily dose
40
subject has role
antihypertensive drug
Sources (6)

via Wikidata · CC0

~4 min read

Encyclopedic overview

9 sections
Contents
  • Medical uses
  • Side effects
  • Pharmacology
  • Pharmacodynamics
  • Pharmacokinetics
  • Chemistry
  • Society and culture
  • Availability
  • References

Penbutolol (brand names Levatol, Levatolol, Lobeta, Paginol, Hostabloc, Betapressin) is a medication in the class of beta blockers, used in the treatment of high blood pressure. Penbutolol is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective β blocker. Penbutolol is a sympathomimetic drug with properties allowing it to act as a partial agonist at β adrenergic receptors.

It was approved by the FDA in 1987 and was withdrawn from the US market by January 2015.

Excerpted from Wikipedia’s “penbutolol” article, available under the CC BY-SA 4.0 licence.